Protein Identification of Mixture Samples by LC/MS/MS and Proteomic Profiling of ASO treated Brain Organoids

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued.

The solicitation number is 75N95024Q00422 and the solicitation is issued as a request for quotation (RFQ).
    
This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13—Simplified Acquisition Procedures;  and FAR Part 12—Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold.

THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME).  

The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Poochon Scientific LLC, 5350 Partners Court, STE. C, Frederick, MD 21703 for the Protein Identification of Mixture Samples by LC/MS/MS and Proteomic Profiling of ASO treated Brain Organoids.

This acquisition is conducted as non-competitive for a commercial item or service and is conducted pursuant to FAR 13.106-1(b)(1).

The Therapeutic Development Branch (TDB) at the National Center for Advancing Translational Sciences (NCATS) plans to use brain organoids derived from patient’s specific induce pluripotent stem cells (iPSC) as a model system in vitro to test new hypothesis, and establish diseases hallmarks by Liquid Chromatography with tandem mass spectrometry (LC/MS/MS). Furthermore, it will use the model system with proteomic profiling to validate the efficacy of potential therapeutic treatment such as antisense oligonucleotides (ASO). See Attachment 1 - Statement of Work.